Adagene to Present on ADG126 and Pembrolizumab Combo at ESMO Congress

Adagene Incorporated, a clinical-stage biotechnology firm listed on Nasdaq under the ticker ADAG, is pioneering the development of innovative antibody-based therapies. The company recently announced its participation in the ESMO Congress, scheduled to be held in Barcelona, Spain, from September 13-17, 2024. During the event, Adagene will present a poster detailing the findings from its ongoing phase 1b/2 clinical trial involving its masked anti-CTLA-4 SAFEbody combined with pembrolizumab, an anti-PD-1 treatment.

The poster presentation is titled, "Increased Therapeutic Index of Muzastotug (Muza, ADG126), a Masked Anti-CTLA-4 SAFEbody®, in Combination with Pembrolizumab (Pembro) Enables Significant Clinical Benefits and Supports Further Clinical Development in Patients with Metastatic MSS CRC." This presentation will be available on Adagene's website in line with the ESMO embargo policy.

Adagene employs a platform-driven approach to revolutionize cancer immunotherapy. The company's innovative methods utilize computational biology and artificial intelligence to design unique antibodies tailored to meet unmet medical needs globally. Adagene has established strategic partnerships with renowned global entities, harnessing its SAFEbody® precision masking technology across various scientific frontiers.

At the core of Adagene's innovation is its proprietary Dynamic Precision Library (DPL) platform, which includes NEObody™, SAFEbody, and POWERbody™ technologies. This platform underpins a robust pipeline of novel immunotherapy programs. The SAFEbody technology, in particular, addresses the safety and tolerability challenges commonly associated with antibody therapies. By employing precision masking, it shields the binding domain of biologic therapies, ensuring that antibodies target tumors specifically while minimizing impact on healthy tissues.

Adagene's flagship clinical program, ADG126 (muzastotug), exemplifies this technology. ADG126 is a masked, anti-CTLA-4 SAFEbody that targets a specific epitope of CTLA-4 in regulatory T cells within the tumor microenvironment. Currently, ADG126 is undergoing phase 1b/2 clinical trials in combination with anti-PD-1 therapy, focusing on patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). The SAFEbody platform’s versatility allows its application in various antibody-based therapeutics, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.

Adagene's mission is to leverage cutting-edge technology to improve the efficacy and safety of cancer treatments. The company's ongoing research and development efforts aim to expand its reach and impact, addressing critical gaps in cancer therapy. Through its collaborations and innovative approaches, Adagene is poised to make significant contributions to the field of immuno-oncology.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!